Published in Med Toxicol on December 29, 1986
Amanita phalloides-type mushroom poisoning. West J Med (1982) 2.26
Randomized study of the treatment of phenobarbital overdose with repeated doses of activated charcoal. JAMA (1984) 1.58
Mechanisms of inhibition of tolbutamide metabolism: phenylbutazone, oxyphenbutazone, sulfaphenazole. Clin Pharmacol Ther (1977) 1.49
The dopamine transporter gene and Parkinson's disease in a Chinese population. Neurology (1997) 1.43
Management of theophylline overdose patients in the intensive care unit. Anaesth Intensive Care (1992) 1.39
Altered methadone pharmacokinetics in methadone-maintained pregnant women. J Pharmacol Exp Ther (1985) 1.35
Relationship between phenytoin and tolbutamide hydroxylations in human liver microsomes. Br J Clin Pharmacol (1991) 1.34
Amatoxin poisoning in northern California, 1982-1983. West J Med (1986) 1.31
Failure of haemoperfusion and haemodialysis to prevent death in paraquat poisoning. A retrospective review of 42 patients. Med Toxicol Adverse Drug Exp (1988) 1.23
Conversion of irinotecan (CPT-11) to its active metabolite, 7-ethyl-10-hydroxycamptothecin (SN-38), by human liver carboxylesterase. Biochem Pharmacol (1996) 1.18
Experience with 732 acute overdose patients admitted to an intensive care unit over six years. Med J Aust (1993) 1.12
Identification and properties of a major plasma metabolite of irinotecan (CPT-11) isolated from the plasma of patients. Cancer Res (1996) 1.11
The epidemiology of Parkinson's disease in an Australian population. Neuroepidemiology (1998) 1.08
First-pass elimination. Basic concepts and clinical consequences. Clin Pharmacokinet (1984) 1.06
Potential pitfalls in the evaluation of the usefulness of hemodialysis for the removal of lithium. J Toxicol Clin Toxicol (1982) 1.05
Diuresis, dialysis, and hemoperfusion. Indications and benefits. Emerg Med Clin North Am (1984) 0.97
Serum formate concentrations in methanol intoxication as a criterion for hemodialysis. Ann Intern Med (1986) 0.95
Toxicologic studies in a fatal overdose of 2,4-D, MCPP, and chlorpyrifos. J Anal Toxicol (1983) 0.93
The association between polymorphisms in the cytochrome P-450 2D6 gene and Parkinson's disease: a case-control study and meta-analysis. J Neurol Sci (1997) 0.92
Large scale production and purification of paraquat and desipramine monoclonal antibodies and their Fab fragments. Int J Immunopharmacol (1988) 0.89
Effects of nifedipine on psychosis and tardive dyskinesia in schizophrenic patients. J Clin Psychopharmacol (1991) 0.89
"Profiting" from vegetables. J Toxicol Clin Toxicol (1996) 0.89
Phenytoin-induced methadone withdrawal. Ann Intern Med (1981) 0.89
Purification and characterization of two human liver carboxylesterases. Int J Biochem (1989) 0.89
Removal of theophylline from the body by haemoperfusion. Clin Pharmacokinet (1979) 0.88
Albumin enhances unidirectional fluxes of fatty acid across a lipid-water interface: theory and experiments. Am J Physiol (1989) 0.87
Quantitative analysis of two pyridinium metabolites of haloperidol in patients with schizophrenia. Clin Pharmacol Ther (1994) 0.87
Presystemic metabolism of meperidine to normeperidine in normal and cirrhotic subjects. Clin Pharmacol Ther (1981) 0.87
Activation of the food-derived mutagen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine by rabbit and human liver microsomes and purified forms of cytochrome P-450. Carcinogenesis (1989) 0.85
Two fatalities after acute occupational exposure to ethylene dibromide. JAMA (1984) 0.84
Effects of tricyclic antidepressants on drug metabolism. Clin Pharmacol Ther (1975) 0.84
Formation of pyridinium species of haloperidol in human liver and brain. Psychopharmacology (Berl) (1996) 0.84
Theophylline overdose: acute single ingestion versus chronic repeated overmedication. Am J Emerg Med (1985) 0.83
Biliary excretion of diflunisal conjugates in patients with T-tube drainage. Eur J Clin Pharmacol (1988) 0.83
Benefit of hemoperfusion in acute theophylline intoxication. J Toxicol Clin Toxicol (1984) 0.83
Effects on the liver of chemicals encountered in the workplace. West J Med (1982) 0.83
Efficacy of single or repeated hemoperfusion in a canine model of paraquat poisoning. J Pharmacol Exp Ther (1990) 0.83
Cortisol metabolism and its inhibition by glycyrrhetinic acid in the isolated perfused human placental lobule. J Steroid Biochem Mol Biol (1997) 0.82
The effects of aging and nutritional state on hypoxia-reoxygenation injury in the perfused rat liver. Transplantation (1994) 0.82
Combined hepatic and renal injury in alcoholics during therapeutic use of acetaminophen. Arch Intern Med (1985) 0.82
Metabolic disposition of simvastatin in patients with T-tube drainage. Drug Metab Dispos (1994) 0.81
Quantitation of paraquat in biological samples by radioimmunoassay using a monoclonal antibody. Fundam Appl Toxicol (1992) 0.81
Improved therapeutic drug monitoring of tacrolimus (FK506) by tandem mass spectrometry. Clin Chem (1997) 0.81
A high-performance liquid chromatography-electrospray-tandem mass spectrometry analysis of cortisol and metabolites in placental perfusate. Anal Biochem (1997) 0.81
Prevention of paraquat toxicity in suspensions of alveolar type II cells by paraquat-specific antibodies. Hum Exp Toxicol (1994) 0.81
Two pyridinium metabolites of haloperidol are present in the brain of patients at post-mortem. Life Sci (1997) 0.81
Clinical and neuropathological abnormalities in baboons treated with HPTP, the tetrahydropyridine analog of haloperidol. Exp Neurol (1999) 0.81
The effects of allopurinol and clofibrate on the elimination of coumarin anticoagulants in man. Aust N Z J Med (1975) 0.81
Lack of effect of diazepam on methadone metabolism in methadone-maintained addicts. Clin Pharmacol Ther (1982) 0.81
Further characterisation of the interaction of haloperidol metabolites with neurotransmitter transporters in rat neuronal cultures and in transfected COS-7 cells. Naunyn Schmiedebergs Arch Pharmacol (2000) 0.80
Calibration of albumin-fatty acid binding constants measured by heptane-water partition. Am J Physiol (1993) 0.80
Diflunisal and its conjugates in patients with renal failure. Br J Clin Pharmacol (1991) 0.80
Identification of potentially neurotoxic pyridinium metabolite in the urine of schizophrenic patients treated with haloperidol. Biochem Biophys Res Commun (1991) 0.80
Effect of phenytoin on meperidine clearance and normeperidine formation. Clin Pharmacol Ther (1981) 0.79
Sensitive, specific quantitative analysis of tacrolimus (FK506) in blood by liquid chromatography-electrospray tandem mass spectrometry. Clin Chem (1996) 0.79
The midbrain dopaminergic cell groups in the baboon Papio ursinus. Brain Res Bull (1998) 0.79
Pretreatment with drug-specific antibody reduces desipramine cardiotoxicity in rats. Life Sci (1991) 0.78
Survival after unexpected high serum methotrexate concentrations in a patient with osteogenic sarcoma. Drug Saf (1991) 0.78
Studies of protein interactions by biosensor technology: an alternative approach to the analysis of sensorgrams deviating from pseudo-first-order kinetic behavior. Anal Biochem (1997) 0.78
Lack of gastrointestinal metabolism of propranolol in dogs after portacaval transposition. J Pharmacol Exp Ther (1982) 0.78
Metabolism of haloperidol to pyridinium species in patients receiving high doses intravenously: is HPTP an intermediate? Life Sci (1997) 0.78
Hepatic intracellular pH during the prereplicative period following partial hepatectomy. Am J Physiol (1993) 0.78
Metabolic drug interactions--a critical review. Med J Aust (1975) 0.78
Reversal of desipramine toxicity in rats using drug-specific antibody Fab' fragment: effects on hypotension and interaction with sodium bicarbonate. J Pharmacol Exp Ther (1992) 0.77
Granulomatous thyroiditis and lithium therapy. Aust N Z J Med (1992) 0.77
Nonlinear relationship between circulating concentrations of reduced haloperidol and haloperidol: evaluation of possible mechanisms. Psychopharmacology (Berl) (1994) 0.77
Redistribution into plasma of tracer doses of desipramine by anti-desipramine antiserum in rats. Biochem Pharmacol (1987) 0.77
Glucose transport and hypoxia-reoxygenation injury in the perfused rat liver. J Gastroenterol Hepatol (1994) 0.77
Ethylesterases as indicators of liver damage. I. Studies on malathion carboxylesterases. Toxicol Appl Pharmacol (1982) 0.77
Concurrent intravenous administration of a labeled tracer to determine the oral bioavailability of a drug exhibiting Michaelis-Menten metabolism. J Pharmacokinet Biopharm (1987) 0.77
Dose-dependent sulfoconjugation of salicylamide in dogs: effect of sulfate depletion or administration. J Pharmacol Exp Ther (1985) 0.77
Competition between paraquat and putrescine for uptake by suspensions of rat alveolar type II cells. Biochem Pharmacol (1992) 0.77
Disposition of epirubicin after intraarterial administration in Lipiodol to patients with hepatocellular carcinoma. Ther Drug Monit (1996) 0.77
Comparison of high-performance liquid chromatography and monoclonal fluorescence polarization immunoassay for the determination of whole-blood cyclosporin A in liver and heart transplant patients. Ther Drug Monit (1994) 0.76
Effects of specific antibody Fab fragments on desipramine pharmacokinetics in the rat in vivo and in the isolated, perfused liver. J Pharmacol Exp Ther (1995) 0.76
Ultrastructure of canine lung during the proliferative phase of paraquat toxicity. Br J Exp Pathol (1988) 0.76
The effects of differential induction of cytochrome P-450, carboxylesterase and glutathione S-transferase activities on malathion toxicity in mice. Toxicol Appl Pharmacol (1987) 0.76
Massive intoxication with acetaminophen and propoxyphene: unexpected survival and unusual pharmacokinetics of acetaminophen. J Toxicol Clin Toxicol (1982) 0.76
Potencies of haloperidol metabolites as inhibitors of the human noradrenaline, dopamine and serotonin transporters in transfected COS-7 cells. Naunyn Schmiedebergs Arch Pharmacol (1999) 0.76
Redistribution of tricyclic antidepressants in rats using a drug-specific monoclonal antibody: dose-response relationship. Drug Metab Dispos (1991) 0.76
The serotonin transporter gene and Parkinson's disease. Eur Neurol (2000) 0.76
An evaluation of the effects of lithium in the treatment of chronic alcoholism. I. Clinical results. Alcohol Clin Exp Res (1981) 0.76
Stereospecific reduction of haloperidol in human tissues. Biochem Pharmacol (1992) 0.76
Sensitive high-performance liquid chromatographic assay with ultraviolet detection of methadone enantiomers in plasma. J Chromatogr B Biomed Appl (1994) 0.76
Determination of methadone and its primary metabolite in biologic fluids using gas chromatography with nitrogen-phosphorus detection. J Anal Toxicol (1982) 0.76
Enhanced bioavailability of pethidine and pentazocine in patients with cirrhosis of the liver. Aust N Z J Med (1980) 0.76
Cloning and analysis of a cDNA encoding a human liver carboxylesterase. Gene (1991) 0.76
Intestinal infarction complicating phenobarbital overdose. Arch Intern Med (1984) 0.76
Diltiazem overdose in an elderly patient: efficacy of adrenaline. Anaesth Intensive Care (1992) 0.75
Nonlinear formation of propranolol metabolites in dogs after portacaval transpositions. J Pharmacokinet Biopharm (1984) 0.75
Pharmacokinetics and toxicity of high doses of antibody Fab fragments in rats. Drug Metab Dispos (1988) 0.75
Prescription for poisoning. Med J Aust (1995) 0.75
Drug-specific F(ab')2 fragment reduces desipramine cardiotoxicity in rats. Int J Immunopharmacol (1991) 0.75
Diazepam kinetics in acute alcohol withdrawal. Clin Pharmacol Ther (1979) 0.75
Lack of efficacy of plasmapheresis in a patient overdosed with thyroxine. Anaesth Intensive Care (1994) 0.75
The importance of electrostatic interactions in the binding of paraquat to its elicited monoclonal antibody. Mol Immunol (1990) 0.75
Determination of haloperidol and reduced haloperidol in the plasma and blood of patients on depot haloperidol. Psychopharmacology (Berl) (1992) 0.75
Aging and the response of the isolated perfused rat liver to vasoactive drugs. Biochem Pharmacol (1992) 0.75
Adaptation of the Müller method to allow quantitative characterization of the affinity and cross-reactivity of antibodies by competitive radioimmunoassay. Mol Immunol (1991) 0.75
Concurrent determination of hepatic bioavailability of salicylamide by three techniques in the dog. J Pharm Sci (1989) 0.75